Last reviewed · How we verify
KQ-2003 CAR T-cells
At a glance
| Generic name | KQ-2003 CAR T-cells |
|---|---|
| Sponsor | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome (PHASE1)
- A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KQ-2003 CAR T-cells CI brief — competitive landscape report
- KQ-2003 CAR T-cells updates RSS · CI watch RSS
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd. portfolio CI